- Home
- LQDA
LQDA
Liquidia Corporation
as 11-22-2024 4:00pm EST
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | MORRISVILLE |
| Market Cap: | 856.5M | IPO Year: | 2018 |
| Target Price: | $27.14 | AVG Volume (30 days): | 773.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.62 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.69 - $16.99 | Next Earning Date: | 11-13-2024 |
| Revenue: | $15,610,000 | Revenue Growth: | -14.78% |
| Revenue Growth (this year): | -8.41% | Revenue Growth (next year): | 227.73% |
Stock Insider Trading Activity of Liquidia Corporation (LQDA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Adair Jason | LQDA | Chief Business Officer | Oct 28 '24 | Sell | $11.31 | 459 | $5,190.42 | 118,115 | |
| Moomaw Scott | LQDA | Chief Commercial Officer | Oct 14 '24 | Sell | $11.11 | 1,527 | $16,961.46 | 152,798 | |
| JEFFS ROGER | LQDA | Chief Executive Officer | Oct 14 '24 | Sell | $11.11 | 8,053 | $89,450.31 | 812,193 | |
| Kaseta Michael | LQDA | CFO and COO | Oct 14 '24 | Sell | $11.11 | 3,892 | $43,231.17 | 311,076 | |
| Saggar Rajeev | LQDA | Chief Medical Officer | Oct 14 '24 | Sell | $11.11 | 2,260 | $25,103.40 | 207,383 | |
| Adair Jason | LQDA | Chief Business Officer | Oct 11 '24 | Sell | $11.11 | 1,146 | $12,729.42 | 118,115 | |
| Manning Paul B | LQDA | Director | Sep 12 '24 | Buy | $8.90 | 337,078 | $2,999,994.20 | 816,311 | |
| Caligan Partners LP | LQDA | Director10% Owner | Aug 30 '24 | Buy | $9.51 | 150,000 | $1,426,500.00 | 6,994,997 | |
| Moomaw Scott | LQDA | Chief Commercial Officer | Aug 30 '24 | Sell | $9.50 | 546 | $5,186.84 | 152,798 | |
| Kaseta Michael | LQDA | CFO and COO | Aug 30 '24 | Sell | $9.50 | 1,079 | $10,250.18 | 311,076 |
Latest Liquidia Corporation News
LQDA Breaking Stock News: Dive into LQDA Ticker-Specific Updates for Smart Investing
Simply Wall St.
5 days ago
3 US Growth Stocks With At Least 10% Insider Ownership
Simply Wall St.
9 days ago
Liquidia Third Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
10 days ago
Liquidia Corp (LQDA) Q3 2024 Earnings Call Highlights: Strategic Advances Amidst Regulatory ...
Zacks
11 days ago
Liquidia Technologies, Inc. (LQDA) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
11 days ago
Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
12 days ago
Liquidia to Present at the Stifel 2024 Healthcare Conference
GuruFocus.com
16 days ago
Earnings To Watch: Liquidia Corp (LQDA) Reports Q3 2024 Result
Zacks
17 days ago
Arcellx (ACLX) Stock Jumps 6.7%: Will It Continue to Soar?
Compare LQDA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LQDA Liquidia Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.